Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Fatal or non‐fatal serious adverse events · people with primary hypertension
Renin inhibitors showed no clear difference in fatal or non‐fatal serious adverse events compared with ACE inhibitors (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (number of people) · people with liver cirrhosis and ascites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events for neonate/infant · pregnant women and their babies
The intervention may leads to lower serious adverse events for neonate/infant (low certainty).
1 finding from 1 review
Serious adverse events (during admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found